Servier Partners with Mitsubishi to Promote Diabetes Treatment in China

Servier Pharma (Tianjin) signed a strategic cooperation agreement with Mitsubishi Tanabe Pharma to promote Mitsubishi's type 2 diabetes treatment drug Tenelia® (teneligliptin), a DPP-4 inhibitor, in mainland China. MTPC has completed the China Phase III clinical studies of Tenelia. The agreement was signed between Servier, a Paris headquartered biopharma, and Tianjin Tanabe Seiyaku, a JV formed by Tianjin Lisheng Pharma and Mitshubishi. More details.... Share this with colleagues: // //